Suppr超能文献

评估当代和历史 von Willebrand 因子(VWF)检测在实验室鉴定 von Willebrand 病(VWD)中的性能:澳大利亚经验。

Evaluating Performance of Contemporary and Historical von Willebrand Factor (VWF) Assays in the Laboratory Identification of von Willebrand Disease (VWD): The Australasian Experience.

机构信息

Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia.

Sydney Centers for Thrombosis and Haemostasis, Westmead, New South Wales Australia.

出版信息

Semin Thromb Hemost. 2022 Sep;48(6):711-731. doi: 10.1055/s-0042-1753528. Epub 2022 Jul 8.

Abstract

von Willebrand disease (VWD) is a common bleeding disorder that arises from deficiency and/or defects of von Willebrand factor (VWF). Appropriate diagnosis of VWD, including differential identification of qualitative (types 2A, 2B, 2M, 2N VWD) quantitative (types 1 and 3 VWD) defects remains problematic but has important management implications, given differential therapy. Complete assessment for VWD in a patient with a bleeding history requires comprehensive test panels, including VWF activity and antigen. We describe the Australasian experience, using data from the Royal College of Pathologists of Australasia (RCPA) Quality Assurance Program (QAP) related to VWF testing in their VWD test module. The RCPAQAP has been providing samples for VWF testing since 1998, representing 25 years of proficiency testing related to VWD diagnosis. A total of 109 samples have been dispatched to participants over these years, with current assessment involving dispatches of two samples (=4 samples) per year. Samples have represented all types of VWD, as well as normal or other samples, including acquired von Willebrand syndrome and plasma VWF concentrates as used in VWD therapy. Different VWF assays and activity/antigen ratios show different utility in VWD and type identification. In the past 9 years of data capture, a total of 166 errors were identified from a total of 1,839 interpretations, representing a base error rate of 9.0%. Identification errors were highest for type 2 VWD samples (15.3%), intermediate for type 1 VWD samples (7.5%), and lowest for normal samples (2.4%). Errors can be linked to assay limitations, including assay variability and low-level VWF detection limits, as well as laboratory issues (including test result misinterpretation, which accounts for approximately 40% of all errors for type 2 VWD). For test-associated errors, VWF:RCo and VWF:GPIbM were associated with the highest variability and error rate, which was up to 10x higher than that using VWF:CB. As a test group, chemiluminescence-based procedures were associated with lowest inter-laboratory variability, best low-level VWF detection (down to <1 U/dL), and least errors overall. These findings inform on reasons behind high rates of errors associated with VWD diagnosis, with some assays and methodologies performing substantially better than others.

摘要

血管性血友病(von Willebrand disease,VWD)是一种常见的出血性疾病,由血管性血友病因子(von Willebrand factor,VWF)缺乏和/或缺陷引起。VWD 的适当诊断,包括定性(2A、2B、2M、2N 型 VWD)和定量(1 型和 3 型 VWD)缺陷的鉴别诊断仍然存在问题,但鉴于不同的治疗方法,这具有重要的管理意义。对有出血史的患者进行 VWD 全面评估需要全面的检测项目,包括 VWF 活性和抗原。我们描述了澳大利亚的经验,使用了皇家病理学家学院(Royal College of Pathologists of Australasia,RCPA)质量保证计划(Quality Assurance Program,QAP)中与 VWD 测试模块相关的 VWF 测试数据。自 1998 年以来,RCPAQAP 一直在提供 VWF 测试样本,代表了与 VWD 诊断相关的 25 年的能力验证。多年来,共向参与者发送了 109 个样本,目前每年评估两次样本(=4 个样本)。这些样本代表了所有类型的 VWD,以及正常或其他样本,包括获得性血管性血友病综合征和用于 VWD 治疗的血浆 VWF 浓缩物。不同的 VWF 检测方法和活性/抗原比值在 VWD 和类型识别中具有不同的应用价值。在过去 9 年的数据采集过程中,在总共 1839 次解释中,共发现了 166 次错误,这意味着基础错误率为 9.0%。2 型 VWD 样本的识别错误最高(15.3%),1 型 VWD 样本的识别错误次之(7.5%),正常样本的识别错误最低(2.4%)。错误可归因于检测方法的局限性,包括检测方法的变异性和低水平 VWF 的检测限,以及实验室问题(包括对检测结果的错误解释,这占 2 型 VWD 所有错误的约 40%)。对于与检测相关的错误,VWF:RCo 和 VWF:GPIbM 与最高的变异性和错误率相关,最高可达 10 倍于 VWF:CB 的错误率。作为一个检测组,基于化学发光的检测程序与实验室间最低的变异性、最佳的低水平 VWF 检测能力(低至<1 U/dL)和总体最低的错误率相关。这些发现解释了与 VWD 诊断相关的高错误率背后的原因,某些检测方法和方法明显优于其他方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验